ArticleTobacco induced diseases2020
Smoking prevalence among tuberculosis patients: A crosssectional study in Bangladesh and Pakistan.
Article in Tobacco induced diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Prevalence of cardiovascular risk factors in active tuberculosis in Africa: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Trial
- Embedding community engagement in tuberculosis (TB) research: evidence from urban Bangladesh.Research involvement and engagement · 2026Article
- Cost-effectiveness of a mTB-Tobacco intervention for smoking cessation in people with tuberculosis: an economic evaluation of a cluster randomised controlled trial.The Lancet regional health. Southeast Asia · 2026Article
- Article
- Unraveling the Drivers of Tuberculosis: A Retrospective Panel Data Study Across 70 Developing Countries.Health science reports · 2025Article
- Article
- High prevalence of current tobacco smoking among patients with tuberculosis and people living with HIV in Jordan: A cross-sectional survey.Tobacco induced diseases · 2023Article
- Effectiveness of Nicotine Replacement Therapy on Smoking Cessation and Reduction Among Pulmonary Tuberculosis Patients - A Randomized Controlled Trial.International journal of preventive medicine · 2023Article
- Prevalence of modifiable risk factors of tuberculosis and their population attributable fraction in Iran: A cross-sectional study.PloS one · 2022Article
- The syndemic challenge of tuberculosis and tobacco use.Tobacco induced diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionSmoking has a negative impact on TB outcomes. We estimated the proportion of TB patients who smoke and are willing to quit in two high TB burden countries, Bangladesh and Pakistan.
methodsA cross-sectional survey was conducted among TB patients to assess their eligibility and recruit them to a smoking cessation randomized controlled trial. Adults diagnosed with TB were recruited from 32 health facilities in Bangladesh and Pakistan. Data on smoking behaviour and willingness to quit were collected and analysed.
resultsIn total, 13934 TB patients completed the survey between June 2017 and April 2018. The prevalence of smoking in these TB patients was estimated to be 22.5% (95% CI: 21.8, 23.2). Moreover, the prevalence of smoking in TB patient population was 8% (RR=1.49; 95% CI: 7.1-8.9; p<0.01) and 8.3% (RR=1.24; 95% CI: 7.3-9.4; p<0.01) higher than smoking prevalence in the general population in Bangladesh and Pakistan, respectively. Among TB patients who smoke, 97.7% (95% CI: 97.2-98.2) were willing to quit.
conclusionsThe estimated prevalence of smoking was higher in TB patients than the general population; however, a vast majority of TB patients who smoke were willing to quit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.